BiAIM Action Biopharmaceutical

BiAIM Action Biopharmaceutical is a clinical-stage biotechnology company focused on the discovery and development of next-generation multi-functional antibody therapeutics for oncology and autoimmune diseases. The company utilizes its proprietary BiAIM platform to engineer innovative biologics, including bispecific antibodies and fusion proteins, designed to overcome resistance to current immunotherapies. Their lead programs target well-validated pathways such as PD-1/PD-L1 and CTLA-4 while incorporating additional mechanisms to modulate the tumor microenvironment. Headquartered in Suzhou, China, BiAIM Action aims to provide more effective treatment options for patients with refractory or relapsed cancers through precision protein engineering.